Menu Search
Equities

TOT BIOPHARM International Co Ltd

1875:HKG.HS

TOT BIOPHARM International Co Ltd

Actions
  • Price (HKD)2.00
  • Today's Change0.00 / 0.00%
  • Shares traded98.80k
  • 1 Year change0.00%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year TOT BIOPHARM International Co Ltd has grown net income from a loss of -49.92m to a smaller loss of -37.76m primarily through revenue growth (442.18m to 780.63m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the 76.54% growth in revenues contributed enough to still see net income improve.
Gross margin72.02%
Net profit margin0.92%
Operating margin1.52%
Return on assets0.64%
Return on equity1.25%
Return on investment0.84%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at TOT BIOPHARM International Co Ltd fell by 66.17m. However, the company earned 56.43m from its operations for a Cash Flow Margin of 7.23%. In addition the company generated 38.23m cash from financing while 164.11m was spent on investing.
Cash flow per share0.0964
Price/Cash flow per share22.12
Book value per share1.03
Tangible book value per share1.02
More ▼

Balance sheet in CNYView more

TOT BIOPHARM International Co Ltd has a Debt to Total Capital ratio of 34.65%, a lower figure than the previous year's 40.60%.
Current ratio1.94
Quick ratio1.63
Total debt/total equity0.5303
Total debt/total capital0.3465
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.